The clinical study investigating the effect of pemafibrate administration on cardiac diastolic function in patients with type 2 diabetes

The clinical study investigating the effect of pemafibrate administration on cardiac diastolic function in patients with type 2 diabetes - The effect of pemafibrate on cardiac diastolic function in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041707

Enrollment

Registered

2020-09-23

Start date

2020-09-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes, Dyslipidemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who is diagnosed type 2 diabetes and hypertriglyceridemia (reference value: fasting triglyceride above 150mg/dL). 2)Patients who will be administered with pemafibrate. 3)Patients who understand this study and agree to written consent to participating in it based on sufficient explanations.

Exclusion criteria

Exclusion criteria: 1) Who has a history of fibrate exposure within 6 months. 2) Who suffers from atrial fibrillation. 3) Who is judged by the investigators to be inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
Left ventricular inflow blood velocity waveform (before versus 8-16 weeks after pemafibrate administration)	—

Secondary

Measure	Time frame
Mitral annulus TDI, Pulmonary blood flow pressure waveform, AST, ALT, ALP, gammaGTP, Triglyceride, Free Fatty Acid, BNP(before versus 8-16 weeks after pemafibrate administration)	—

Countries

Japan

Contacts

Public ContactYasuharu Ohta

Yamaguchi University, Graduate School of Medicine Division of Endocrinology, Metabolism, Hematological Science and Therapeutics

yohta@yamaguchi-u.ac.jp0836-22-2251

Outcome results